UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Interrogation of transcriptomic changes associated with drug-induced hepatic sinusoidal dilatation in colorectal cancer

PloS one, 2018-06, Vol.13 (6), p.e0198099

2018

Volltextzugriff (PDF)

Molecular classification of human cancers using a 92-gene real-time quantitative polymerase chain reaction assay

Archives of pathology & laboratory medicine (1976), 2006-04, Vol.130 (4), p.465-473

2006

Volltextzugriff (PDF)

Targeted biomarker profiling of matched primary and metastatic estrogen receptor positive breast cancers

PloS one, 2014-02, Vol.9 (2), p.e88401-e88401

2014

Volltextzugriff (PDF)

Next generation MUT-MAP, a high-sensitivity high-throughput microfluidics chip-based mutation analysis panel

PloS one, 2014-03, Vol.9 (3), p.e90761-e90761

2014

Volltextzugriff (PDF)

Mutation scanning using MUT-MAP, a high-throughput, microfluidic chip-based, multi-analyte panel

PloS one, 2012-12, Vol.7 (12), p.e51153-e51153

2012

Volltextzugriff (PDF)

A Novel Method for Mutation Analysis Using Genomic DNA Obtained from Immunohistochemistry-Stained Sections

Journal of Molecular Biomarkers & Diagnosis, 2015, Vol.6 (2)

Rajesh Patel, Rupal Desai

2015

Volltextzugriff (PDF)

VERONICA: Randomized Phase II Study of Fulvestrant and Venetoclax in ER-Positive Metastatic Breast Cancer Post-CDK4/6 Inhibitors - Efficacy, Safety, and Biomarker Results

Clinical cancer research, 2022-08, Vol.28 (15), p.3256-3267

2022

Volltextzugriff (PDF)

Efficacy, Safety, and Pharmacodynamic Effects of the Bruton’s Tyrosine Kinase Inhibitor Fenebrutinib (GDC‐0853) in Systemic Lupus Erythematosus: Results of a Phase II, Randomized, Double‐Blind, Placebo‐Controlled Trial

Arthritis & rheumatology (Hoboken, N.J.), 2021-10, Vol.73 (10), p.1835-1846

2021

Volltextzugriff (PDF)

Abstract P5-13-06: Exploratory biomarker analysis in VERONICA, a phase 2 study of venetoclax + fulvestrant versus fulvestrant in patients with estrogen receptor (ER)-positive HER2-negative metastatic breast cancer (mBC)

Cancer research (Chicago, Ill.), 2022-02, Vol.82 (4_Supplement), p.P5-P5-13-06

2022

Volltextzugriff (PDF)

Abstract OT-28-03: VICKI: A Phase Ib/II, randomized, placebo-controlled, study of venetoclax plus ado-trastuzumab emtansine (T-DM1) in patients (pts) with previously treated HER2-positive locally advanced (LA) or metastatic breast cancer (MBC)

Cancer research (Chicago, Ill.), 2021-02, Vol.81 (4_Supplement), p.OT-28-03-OT-28-03

2021

Volltextzugriff (PDF)

Serum Protein Profiles of Rheumatoid Arthritis Samples –A Case Study

Biosciences, biotechnology research Asia, 2023-06, Vol.20 (2), p.477-485

2023

Volltextzugriff (PDF)

Biomarker Analyses from a Placebo-Controlled Phase II Study Evaluating Erlotinib ± Onartuzumab in Advanced Non-Small Cell Lung Cancer: MET Expression Levels Are Predictive of Patient Benefit

Clinical cancer research, 2014-09, Vol.20 (17), p.4488-4498

2014

Volltextzugriff (PDF)

Results from VERONICA: A randomized, phase II study of second-/third-line venetoclax (VEN) + fulvestrant (F) versus F alone in estrogen receptor (ER)-positive, HER2-negative, locally advanced, or metastatic breast cancer (LA/MBC)

Journal of clinical oncology, 2021-05, Vol.39 (15_suppl), p.1004-1004

2021

Volltextzugriff (PDF)

An Antibody-Drug Conjugate Directed against Lymphocyte Antigen 6 Complex, Locus E (LY6E) Provides Robust Tumor Killing in a Wide Range of Solid Tumor Malignancies

Clinical cancer research, 2015-07, Vol.21 (14), p.3252-3262

2015

Volltextzugriff (PDF)

I Canʼt Slow Down

Homoeopathic links, 2014-09, Vol.27 (3), p.169-170

Shah, Rupal

2014

Volltextzugriff (PDF)

PAK1 mediates pancreatic cancer cell migration and resistance to MET inhibition

The Journal of pathology, 2014-12, Vol.234 (4), p.502-513

2014

Volltextzugriff (PDF)

Mother “Is Like Your Breath”

Homoeopathic links, 2014-03, Vol.27 (1), p.39-41

Shah, Rupal

2014

Volltextzugriff (PDF)

Abstract 2096: Mechanistic insights into the pathogenesis of anti-DLL4-related hepatic sinusoidal dilatation

Cancer research (Chicago, Ill.), 2016-07, Vol.76 (14_Supplement), p.2096-2096

2016

Volltextzugriff (PDF)

Phase I study of the anti-α5β1 monoclonal antibody MINT1526A with or without bevacizumab in patients with advanced solid tumors

Cancer chemotherapy and pharmacology, 2018-08, Vol.82 (2), p.339-351

2018

Volltextzugriff (PDF)

Co-immunoprecipitation based isolation and identification of Interacting Phytal and Rheumatoid arthritis subject’s serum globulins proteins

Journal of BioScience and Biotechnology, 2024-07, Vol.13 (1), p.61-77

2024

Volltextzugriff (PDF)

Development of a robust RNA-based classifier to accurately determine ER, PR, and HER2 status in breast cancer clinical samples

Breast cancer research and treatment, 2014-11, Vol.148 (2), p.315-325

2014

Volltextzugriff (PDF)

Abstract 4978: Lung cancers regulate the immune suppressor PD-L1 by multiple mechanisms, altering its role in tumor survival

Cancer research (Chicago, Ill.), 2013-04, Vol.73 (8_Supplement), p.4978-4978

2013

Volltextzugriff (PDF)

Abstract 4134: Development of MUT-MAP, a high-throughput multi-analyte mutation panel for cancer biomarkers discovery

Cancer research (Chicago, Ill.), 2013-04, Vol.73 (8_Supplement), p.4134-4134

2013

Volltextzugriff (PDF)

Optimization of a method for preserving nucleic acids in tissue lysates from archival formalin-fixed tissue samples

Clinical cancer research, 2010-10, Vol.16 (19_Supplement), p.B35-B35

2010

Volltextzugriff (PDF)

A novel method for mutation analyses using genomic DNA obtained from IHC-stained sections

Clinical cancer research, 2010-10, Vol.16 (19_Supplement), p.B34-B34

2010

Volltextzugriff (PDF)

1 – 25 von 55

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(48)
Mit Volltextzugriff
(50)

Publikationsform

Artikel
(53)
Buchkapitel
(2)

Sprache

Englisch
(55)
Japanisch
(4)

Erscheinungsjahr

n.n

Thema

Science & Technology
(21)
Life Sciences & Biomedicine
(17)
Humans
(14)
Oncology
(10)
Biology
(8)
Biomarkers
(8)
Female
(8)
Animals
(6)
Cancer
(6)
Gene Expression
(6)
Life Sciences & Biomedicine - Other Topics
(6)
Male
(6)
Tumors
(6)
Mice
(5)
Cancer Therapies
(4)
Genes
(4)
Kinases
(4)
Medicine
(4)
Multidisciplinary Sciences
(4)
Mutation
(4)

15 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 90 Tagen
(1)

Menü

Weitere Dienste

Einstellungen

Interrogation of transcriptomic changes associated with drug-induced hepatic sinusoidal dilatation in colorectal cancer

Molecular classification of human cancers using a 92-gene real-time quantitative polymerase chain reaction assay

Targeted biomarker profiling of matched primary and metastatic estrogen receptor positive breast cancers

Next generation MUT-MAP, a high-sensitivity high-throughput microfluidics chip-based mutation analysis panel

Mutation scanning using MUT-MAP, a high-throughput, microfluidic chip-based, multi-analyte panel

A Novel Method for Mutation Analysis Using Genomic DNA Obtained from Immunohistochemistry-Stained Sections

VERONICA: Randomized Phase II Study of Fulvestrant and Venetoclax in ER-Positive Metastatic Breast Cancer Post-CDK4/6 Inhibitors - Efficacy, Safety, and Biomarker Results

Efficacy, Safety, and Pharmacodynamic Effects of the Bruton’s Tyrosine Kinase Inhibitor Fenebrutinib (GDC‐0853) in Systemic Lupus Erythematosus: Results of a Phase II, Randomized, Double‐Blind, Placebo‐Controlled Trial

Abstract P5-13-06: Exploratory biomarker analysis in VERONICA, a phase 2 study of venetoclax + fulvestrant versus fulvestrant in patients with estrogen receptor (ER)-positive HER2-negative metastatic breast cancer (mBC)

Abstract OT-28-03: VICKI: A Phase Ib/II, randomized, placebo-controlled, study of venetoclax plus ado-trastuzumab emtansine (T-DM1) in patients (pts) with previously treated HER2-positive locally advanced (LA) or metastatic breast cancer (MBC)

Serum Protein Profiles of Rheumatoid Arthritis Samples –A Case Study

Biomarker Analyses from a Placebo-Controlled Phase II Study Evaluating Erlotinib ± Onartuzumab in Advanced Non-Small Cell Lung Cancer: MET Expression Levels Are Predictive of Patient Benefit

Results from VERONICA: A randomized, phase II study of second-/third-line venetoclax (VEN) + fulvestrant (F) versus F alone in estrogen receptor (ER)-positive, HER2-negative, locally advanced, or metastatic breast cancer (LA/MBC)

An Antibody-Drug Conjugate Directed against Lymphocyte Antigen 6 Complex, Locus E (LY6E) Provides Robust Tumor Killing in a Wide Range of Solid Tumor Malignancies

I Canʼt Slow Down

PAK1 mediates pancreatic cancer cell migration and resistance to MET inhibition

Mother “Is Like Your Breath”

Abstract 2096: Mechanistic insights into the pathogenesis of anti-DLL4-related hepatic sinusoidal dilatation

Phase I study of the anti-α5β1 monoclonal antibody MINT1526A with or without bevacizumab in patients with advanced solid tumors

Co-immunoprecipitation based isolation and identification of Interacting Phytal and Rheumatoid arthritis subject’s serum globulins proteins

Development of a robust RNA-based classifier to accurately determine ER, PR, and HER2 status in breast cancer clinical samples

Abstract 4978: Lung cancers regulate the immune suppressor PD-L1 by multiple mechanisms, altering its role in tumor survival

Abstract 4134: Development of MUT-MAP, a high-throughput multi-analyte mutation panel for cancer biomarkers discovery

Optimization of a method for preserving nucleic acids in tissue lysates from archival formalin-fixed tissue samples

A novel method for mutation analyses using genomic DNA obtained from IHC-stained sections

Suchergebnisse filtern